The global cancer supportive care drugs market size was reached at USD 20.96 billion in 2022 and it is projected to hit around USD 25.78 billion by 2032, growing at a CAGR of 2.09% during the forecast period from 2023 and 2032. The rising awareness about adverse effects caused by prolonged cancer treatment is expected to boost the growth of the cancer supportive care drugs market during the analyzed period.
Access our Premium Real Time Data Intelligence Tool, Visit: Precedence Statistics
Cancer supportive care drugs offer wraparound care for cancer patients, and they also help healthcare administration to navigate the illness. Cancer supportive care is a well-recognized discipline that plays around multiple aspects of medical care, including physical, psychological, and mental issues cancer patients face. The evolution in supportive oncology has focused on the improvement of cancer-supportive care drugs that can indicate the urgency of pain.
Supportive care drugs for cancer are widely adopted, and oncologists prefer implementing them from the beginning of the cancer diagnosis. According to the National Cancer Institute, supportive care drugs run a gamut of physical as well as mental well-being.
Supportive care drugs are proven to encompass post-therapy care for cancer patients. Cancer supportive care drugs help alleviate cancer complications and prevent treatment toxicities for cancer patients. Chemotherapy is one of the most effective treatments or therapies for cancer patients. However, prolonged chemotherapy may increase toxicity and reduce the quality of life; supportive cancer care drugs respond to these adverse experiences of cancer treatment. The supportive cancer care drugs or medicines delivery sessions include therapists, palliative care specialists, nutritionists, pain care specialists and medical advisors. Cancer-supportive care drugs have the potential to improve the healthcare experience and quality of life.
The global supportive care drugs market is expected to witness a significant shift during the forecast period owing to the improving supportive oncology sector across the globe. The unhealthy diet and sedentary lifestyles have increased the prevalence of cancer across the globe in the last two decades. According to the World Health Organization (WHO), approximately four lakh children develop cancer each year. Supportive care drugs for cancer patients lessen the pain and effects caused by cancer treatments; the rising prevalence of childhood cancer is expected to grow the demand for supportive care drugs from the healthcare sector.
The increasing concerns about mortality caused by cancer have pushed the oncology sector to bring advanced and accountable treatment for cancer patients; the continuously rising focus on oncology research worldwide is fueling the growth of the cancer-supportive care drugs market. Various cancer treatments often cause serious adverse effects on the human body, and the rising awareness about the severe side effects caused by prolonged cancer treatment poses a driving factor for the market’s growth.
The demand for cancer supportive care drugs is expected to boost from the high-income countries where comprehensive healthcare services are generally available. However, the rising preferences towards targeted molecule therapies for cancer patients will hamper the growth of the cancer-supportive care drugs market.
Report Scope of the Cancer Supportive Care Drugs Market
|Market Size in 2023||USD 21.4 Billion|
|Market Size by 2032||USD 25.78 Billion|
|Growth Rate from 2023 to 2032||CAGR of 2.09%|
|Largest Market||North America|
|Fastest Growing Market||Asia Pacific|
|Forecast Period||2023 to 2032|
|Segments Covered||By Therapeutic Class, By Application and By Distribution Channel|
|Regions Covered||North America, Europe, Asia-Pacific, Latin America and Middle East & Africa|
Rising awareness about the adverse effects of chemotherapy on cancer patients
Chemotherapy is the most common treatment used for cancer treatment globally. Conventional chemotherapy is intended to give short-term or even prolonged hazardous adverse effects, including hair loss, skin infections, vomiting, nausea, loss of appetite, sore mouth, and anemia. Supportive care drugs for cancer patients significantly lessen the hazardous effects by protecting healthy cells and organs before they get affected by cancer cells.
Cancer-supportive care drugs promote tolerance to active therapy and reduce treatment toxicities. According to the article published by the Centers for Medicare and Medicaid Innovation (CMMI) in August 2021, the patients receiving supportive care drugs saw fewer emergencies, hospitalizations, and department visits. Such benefits of supportive cancer care drugs or medicines are expected to drive the growth of the cancer supportive care drugs market with the rising awareness about side effects caused by chemotherapy.
Restrictive policies on the description of opioids
Opioid drugs are widely used in cancer patients to manage severe pain in cancer patients. Opioids are also prescribed for cancer patients undergoing chemotherapy or other treatments, as they provide supportive care. However, opioids are restricted for prescription by considering the severe side effects caused by them, including respiratory issues, depression, osteoporosis, development of other severe disorders, neurological effects, and permanent brain damage.
Opioids may even lead to coma or death. Multiple clinical data suggest that long-term use of opioids can cause erectile dysfunction in men and infertility in women. With this continuing public health crisis, several governments and health ministries are seeking strict laws and restrictions to limit or even restrict the prescription of opioids. Such restrictive policies on opioids will likely hinder the market’s growth.
The rising government focus on improving the oncology sector
With the rising public health concerns, governments across the globe are focused on improving the overall infrastructure of the oncology sector in order to provide quality healthcare services to cancer patients. Many governments around the world are spending on centralized procurement programs and new therapy centers for cancer treatments. For instance, England has set a 10-year long-term plan for cancer to achieve the survivability of cancer patients by 55% before 2028.
Moreover, the Indian government is currently focused on enhancing the number of linear accelerators required in radiation therapy. The rising government focus and spending on improving the oncology sector bring a plethora of opportunities for researchers to bring new and advanced supportive care drugs for cancer patients.
The sudden outbreak of Coronavirus adversely impacted the global cancer supportive care drugs market. The restriction imposed in order to contain the spread of the virus resulted in declined patient visits to the hospitals. The overall reduced number of patients, cancer diagnoses and surgeries negatively impacted the growth of the global cancer supportive care drugs market. Moreover, the disturbed trade market caused disruptions in the supply chain of cancer supportive care drugs globally.
A prolonged halt in research and development (R&D) activities and shutdown of biotech and pharmaceutical companies with workforce shortage resulted in delayed production of cancer supportive care drugs during the critical period of the Covid-19 pandemic. Due to the less immunity power, cancer patients were more vulnerable to getting infected with Coronavirus; this interrupted the routine delivery of cancer supportive care drugs. However, the lockdown and severe risk of infection for cancer patients surged the in-home care segment. They even boosted the growth of online pharmacies owing to the increased preferences for doorstep delivery of prescribed drugs.
Therapeutic Class Insights:
The Granulocyte Colony Stimulating Factors (GCSFs) segment generated more than 27% of revenue share in 2022 and is expected to maintain its dominance during the projected timeframe. Prolonged radiation treatment for cancer may lead to chronic hematologic abnormalities; this condition can put cancer patients at risk of serious infections; GCSFs manage such issues during the cancer treatment. The GCSFs offer the benefits of mobilizing the hematopoietic stem cells during cancer treatment; this factor has boosted the demand for GCSFs in the oncology sector.
On the other hand, the antiemetics segment is expected to witness significant growth during the forecast period. Antiemetics control acute sickness, and the rising demand for anti-sickness drugs for chemotherapy patients is fueling the development of the antiemetics segment.
The breast cancer segment is expected to be the most lucrative segment during the forecast period owing to the rising cases of breast cancer among females across the globe. With the increasing instances of widespread metastasis in which the cancerous cells progress and spread in surrounding breast tissues, the treatment for breast cancer has become more rigorous and costly. To lessen and manage pain during the prolonged treatment of breast cancer, the demand for cancer-supportive care drugs is expected to grow.
Patients who have already gone through radiation therapies for cancer treatment are vulnerable to lung cancer. Moreover, the rising consumption of tobacco and cigarettes is intended to increase the prevalence of lung cancer. Such factors will boost the demand for cancer-supportive care drugs for lung cancer, which enables the growth of the lung cancer segment.
Distribution Channel Insights:
The hospital pharmacy segment holds the largest share in the global cancer supportive care drugs market. The availability of specific medication plans for cancer patients in the hospital pharmacy drives the segment's growth. Moreover, the rising hospitalization of cancer patients in hospitals with advanced care settings is observed to drive the growth of the hospital pharmacy segment.
On the other hand, online pharmacy is expected to witness a noticeable increase during the forecast period due to rising preferences for convenient prescription drug delivery. Value-added services by online pharmacies, such as online doctor consultations and medicine plans, support the growth of the online pharmacy segment. However, the reliability and accountability concerns over online pharmacies may hinder the segment’s growth. Moreover, the improved supply chain in the pharmaceutical sector, along with the rising sales of prescribed cancer medications, are supplementing the development of the retail pharmacy segment.
North America holds the largest share of the global cancer supportive care drugs market; the region is expected to maintain its dominance over the analyzed period. The rapid adoption of the advancements in the pharmaceutical industry is observed as a significant driver for the growth of the cancer supportive care drugs market in North America. The presence of well-established vendors in the supportive care market will maintain the dominance of North America in the cancer supportive care drugs market during the forecast period. Moreover, the rising preferences for supportive care for early-diagnosed cancer patients are supporting the growth of the market in North America. However, the strict restrictions on opioid prescription and sale are creating an obstacle to the development of the cancer supportive care drugs market in North America.
Asia Pacific is the fastest-growing region of the global cancer supportive care drugs market, owing to the increasing demand for supportive care from the oncology sector. Chemotherapy is widely used in the region for treating cancer patients. The rising number of chemotherapies in urban areas is predicted to boost the growth of the cancer supportive care drugs market in Asia Pacific. Moreover, the increasing vendor investments in oncology research will fuel the market’s growth in Asia Pacific.
Germany, England and the United Kingdom are expected to be the most significant contributors to Europe's cancer supportive care drugs market. The rapid increase in breast cancer cases in female patients has boosted the demand for cancer supportive care drugs and palliative care in the region. Several private companies and governmental organizations are investing massive amounts in R&D activities in the oncology research sector to bring more advanced and reliable treatment for cancer patients; this factor is observed to fuel the market’s growth in Europe during the forecast period. The European researchers and healthcare sector are focused on implementing targeted therapies for cancer patients; this factor will likely hamper the growth of the cancer supportive care drugs market in the region.
Key Market Players:
Segments Covered in the Report:
By Therapeutic Class
By Distribution Channel
PROCEED TO BUY :
ASK FOR SAMPLE
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client